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Abstract
Introduction Maladaptive physiological responses to stress
appear to play a role in chronic inflammatory diseases such as
rheumatoid arthritis (RA). However, relatively little stress
research in RA patients has involved the study of pain, the most
commonly reported and most impairing stressor in RA. In the
present study, we compared psychophysical and physiological
responses to standardized noxious stimulation in 19 RA patients
and 21 healthy controls.
Methods Participants underwent a single psychophysical
testing session in which responses to a variety of painful stimuli
were recorded, and blood samples were taken at multiple time
points to evaluate the reactivity of cortisol, interleukin-6 (IL-6),
and tumor necrosis factor-alpha (TNF-α) to the experience of
acute pain.
Results The findings suggest that RA patients display a fairly
general hyperalgesia to mechanical and thermal stimuli across
several body sites. In addition, while serum cortisol levels did not
differ at baseline or following pain testing in patients relative to
controls, the RA patients tended to show elevations in serum IL-
6 and demonstrated enhanced pain-reactivity of serum levels of
TNF-α compared with the healthy controls (P < 0.05).
Conclusions These findings highlight the importance of pain as
a stressor in RA patients and add to a small body of literature
documenting amplified responses to pain in RA. Future studies
of the pathophysiology of RA would benefit from the
consideration of acute pain levels when comparing RA patients
with other groups, and future trials of analgesic interventions in
RA patients may benefit from evaluating the effects of such
interventions on inflammatory activity.
Introduction
Multiple lines of investigation suggest that stress plays a sig-
nificant role in shaping the course of inflammatory diseases
such as rheumatoid arthritis (RA) [1-3]. Stress activates a cas-
cade of neurohumoral events, many of which may be dysregu-
lated in RA patients, including aspects of the hypothalamic-
pituitary-adrenal (HPA) axis, the autonomic nervous system,
and pro-inflammatory processes [1,3]. Dozens of studies over
the past several decades have evaluated the effect of multiple
types of stressors on the physiology and symptomatology of
patients with RA. Collectively, laboratory research has docu-
mented a maladaptively pro-inflammatory response to stress
among RA patients, with elevated stress-reactivity of factors
such as C-reactive protein (CRP) [4] and tumor necrosis fac-
tor-alpha (TNF-α) [5]. Moreover, a relative hypo-responsive-
ness of the autonomic nervous system and HPA system have
been observed in RA patients in response to mental stress as
well as a variety of physical stressors [1,3].
Much stress research in RA has been conducted outside of
the laboratory, and studies of naturally occurring stressors
have revealed that elevations of daily stress among RA
patients are associated with increases in musculoskeletal ten-
derness, interleukin-6 (IL-6) levels, and disease activity [6-9].
ANOVA: analysis of variance; BDI: Beck Depression Inventory; CPT: cold pressor task; CRP: C-reactive protein; DAS28: disease activity score using 
28 joint counts; DMARD: disease-modifying antirheumatic drug; GCRC: general clinical research center; HPA: hypothalamic-pituitary-adrenal; HPTh: 
heat pain threshold; IL-6: interleukin-6; i.v.: intravenous; MTX: methotrexate; PPTh: pressure pain threshold; RA: rheumatoid arthritis; SBP: systolic 
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Interestingly, relatively little of this research has involved the
study of pain, the most commonly reported and most impairing
stressor in RA [10]. The experience of pain is generally asso-
ciated with enhanced release of pro-inflammatory cytokines,
which in turn sensitize the nervous system, promoting a further
amplification of pain transmission [11-14]. To date, a handful
of human studies have documented the presence of cytokine
reactivity to the application of calibrated noxious stimuli in
humans. Significant increases in pro-inflammatory cytokines
such as IL-6 have been observed following non-tissue-damag-
ing painful stimulation in healthy adults [15,16], patients with
juvenile RA [17], and patients with persisting low back pain
[18].
Given that RA patients experience persistent pain and chronic
inflammation, it is natural to inquire whether the inflammatory
response to the experience of pain itself is normal in RA.
Importantly, psychophysical studies indicate that, relative to
controls, RA patients exhibit lower pressure pain thresholds
(PPThs) and enhanced sensitivity to noxious stimuli across a
variety of anatomical sites, including both inflamed joints and
non-inflamed tissues [19-26], suggesting central amplification
of pain-related information. This enhancement of pain sensitiv-
ity appears to be magnified in individuals with RA of longer
duration [25].
To date, although it is well established that RA patients are
more behaviorally responsive to noxious stimulation relative to
non-arthritic controls, no studies have evaluated whether RA
patients show aberrant inflammation-related responses to the
experience of acute pain in a controlled laboratory setting. It is
important to evaluate the inflammatory response to noxious
stimulation among RA patients as daily pain is among their
most common and salient stressors. In the present project, we
focus on assessing IL-6, TNF-α, and cortisol reactivity to acute
painful stimulation in a sample of RA patients compared with
age- and gender-matched healthy controls.
Materials and methods
Participants
Participants were 19 treated RA patients and 21 generally
healthy controls, free from rheumatic disease. RA patients
were recruited via letters and flyers sent to patients of the
Johns Hopkins Arthritis Center, who were diagnosed with RA
using the American College of Rheumatology criteria [27];
controls were recruited through the posting of flyers and the
use of newspaper advertisements around the Baltimore com-
munity. All subjects provided informed consent, and the study
was approved by the Johns Hopkins Institutional Review
Board. None of the authors has any financial or other conflicts
of interest with regard to this study or its findings.
Inclusion criteria for the study (for RA patients) included RA as
the primary source of persistent pain; no current mood or anx-
iety disorder; no history of myocardial infarction or cardiovas-
cular disease; no history of peripheral neuropathy, Raynaud
syndrome, vasculitis, or peripheral vascular disease; no cur-
rent infection; no history of other autoimmune or rheumatic dis-
orders; and no recent history of substance abuse or
dependence. Subjects taking opioid, antidepressant, or ster-
oid medications were not included in the study. Pregnant
women were also not included in the study. Healthy controls
met all of the same criteria; in addition, they did not have RA or
other joint pain and were not taking any centrally acting medi-
cations. RA patients reported being on stable treatment regi-
mens for at least 1 month; those taking non-steroidal anti-
inflammatory medications were asked to abstain from using
them for 24 hours prior to the laboratory session.
Session protocol
All subjects provided verbal and written informed consent, and
all procedures were approved by an institutional review board.
Many of these procedures have been described previously
[16]. The setting for the study was a general clinical research
center (GCRC) based within a university hospital. Participants
arrived between 12 and 12:30 p.m.; they had previously been
requested to refrain from using over-the-counter medications
or caffeine, smoking, or performing other than mild exercise
prior to their arrival. To avoid interfering with RA treatment reg-
imens, participants were asked to take their RA medications as
prescribed. After informed consent and screening for eligibil-
ity, participants completed questionnaires for approximately
10 minutes. Questionnaires included a medical history form,
questions about current pain and current stress levels (rated
on 0-to-10 scales), the Beck Depression Inventory (BDI) [28],
and the Short Form Health Survey-36 (SF-36) [29]. Determi-
nation of eligibility for the study was made based on question-
naires and a medical history taken by a research nurse at the
GCRC.
Next, subjects were seated comfortably in a reclining chair and
an intravenous (i.v.) line was inserted in the left forearm by a
GCRC research nurse [17,30]. After i.v. placement and a 15-
minute period of rest, two baseline blood samples (10 mL),
separated by 5 minutes, were drawn. These two values were
averaged together in order to maximize stability of the baseline
estimates. Baseline systolic and diastolic blood pressures
were then recorded. Subsequently, participants underwent
the psychophysical pain testing procedures described below
(the duration of pain testing was approximately 45 minutes),
after which additional blood samples (10 mL) were taken at
several time points: immediately after testing and 15, 30, and
60 minutes after testing.
Psychophysical pain testing (45-minute session)
Mechanical pain thresholds were assessed first using a digital
pressure algometer (Somedic Production AB, Sollentuna,
Sweden). As in previous studies [19,21,23], we selected sev-
eral muscle/joint sites and bilaterally assessed PPThs. PPThs
were determined twice at each of the following sites on theAvailable online http://arthritis-research.com/content/11/3/R61
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right and left sides of the body in a randomized order: the belly
of the trapezius muscle, the metacarpophalangeal joint of the
thumb, and the quadriceps muscle, near the insertion of the
proximal patellar tendon. At each site, mechanical force was
applied using a 0.5-cm2 probe covered with polypropylene
pressure-transducing material; pressure was increased at a
steady rate of 30 kPa/second until the subject indicated that
the pressure was 'first perceived as painful'.
Next, contact heat stimuli were delivered using a Medoc Ther-
mal Sensory Analyzer (TSA-2001; Medoc Ltd., Ramat Yishai,
Israel). Thermal assessment included sampling of heat pain
thresholds (HPThs) on the ventral forearm using an ascending
method of limits paradigm with a rate of rise of 0.5°C/second
[31]. Three trials of HPTh were performed first, followed by
four trials of suprathreshold heat stimulation. In brief, four
sequences of 10 rapid heat pulses were applied to the fore-
arm, similar to prior studies [32,33]. Within each sequence,
the procedure was as follows: from a 38°C baseline tempera-
ture, 10 successive thermal pulses were delivered. The rate of
rise and fall of the thermode temperature was 10°C/second,
and target temperatures were delivered for approximately 0.5
seconds each. The thermode remained in a fixed position dur-
ing administration of the 10 pulses and then was re-positioned
between sequences, with inter-sequence intervals of 2 min-
utes. Two different target temperatures (49°C and 51°C) were
used two times each in randomized order. Subjects verbally
rated the painfulness of each thermal pulse on a 0-to-100 (0 =
'no pain' and 100 = 'most intense pain imaginable') numeric
rating scale and then rated the painfulness of lingering after-
sensations 15 seconds after the stimuli had ceased [34,35].
Finally, responses to noxious cold were evaluated using a
repeated cold pressor task (CPT), involving immersion of the
right hand in a circulating cold water bath maintained at 4°C.
The CPT is the most commonly used method of pain induction
in the laboratory and has demonstrated clinical relevance
[36,37]. Several recent studies indicate that the CPT provokes
increases in cortisol and norepinepherine as well as producing
increases in pro-inflammatory cytokine production [16,17]. In
the present protocol, participants underwent a series of five
CPTs, with the first four consisting of serial immersions of the
right hand for 30 seconds, with 2 minutes between immer-
sions. The fifth and final CPT involved an immersion of the right
hand lasting until a participant reached pain tolerance (or a 3-
minute maximum). Participants rated the intensity of the cold
pain on a 0-to-100 scale ('no pain' to 'most intense pain imag-
inable') at the midpoint and conclusion of each CPT. Following
the final CPT, participants continued to relax in the chair as
subsequent blood samples were taken.
Physiological measures
Each blood sample (that is, two baseline samples, one sample
immediately after pain testing, then samples at 15, 30, and 60
minutes following the conclusion of pain testing) was col-
lected in a 10-mL tube and transported to the GCRC Core
Laboratory, where it was centrifuged, aliquoted, and stored in
a -80°C freezer for later assay. Serum cortisol was assessed
in duplicate using a radioimmunoassay (Diagnostic Systems
Laboratories, Inc., Webster, TX, USA), with a lower limit of
detection of 0.5 μg/dL, a sensitivity of 0.11 μg/dL, and an
intra-assay coefficient of variation of less than 10%. A stand-
ard high-sensitivity enzyme-linked immunosorbent assay (R&D
Systems, Minneapolis, MN, USA) was used to assess serum
levels of IL-6 in duplicate. This assay has a lower limit of detec-
tion of 0.16 pg/mL, a sensitivity of 0.04 pg/mL, and an intra-
assay coefficient of variation of less than 5%. Similarly, an
enzyme-linked immunosorbent assay from the same company
(R&D Systems) was used to assess serum levels of TNF-α in
duplicate. This assay has a lower limit of detection of 0.25 pg/
mL, a sensitivity of 0.06 pg/mL, and an intra-assay coefficient
of variation of less than 10%.
Data analysis
Simple between-group comparisons (RA patients compared
with controls) were made using analysis of variance (ANOVA).
Changes, across the two groups, in serum levels of cortisol, IL-
6, and TNF-α were evaluated using repeated measures
ANOVA. Inter-relationships among study variables were eval-
uated using Pearson correlations. All analyses were performed
using SPSS (SPSS Inc., Chicago, IL, USA).
Results
RA patients reported a mean time since diagnosis of 8.3 years
(standard deviation = 6.4 years). The mean disease activity
score using 28 joint counts (DAS28) for the sample was 3.1
± 1.4. In addition, the mean CRP level in RA patients was 3.3
± 3.9 μg/ml. These values suggest generally low to moderate
levels of disease activity, on average, in these patients and are
broadly consistent with other, larger US studies of treated RA
patients (for example, in [38], mean RA duration = 12.4 years,
mean DAS28 score = 3.7, and median CRP = 2.6 μg/ml).
RA patients did not differ (all P values of greater than 0.10)
from controls on demographic variables such as age (mean
age for RA patients = 51.7 ± 12.2 years and mean age for
controls = 50.3 ± 12.7 years), gender (58% women in the RA
group and 52% women in the control group), ethnicity (58%
in the RA group were white and 67% in the control group were
white), or education (mean years of education for RA patients
= 14.0 ± 2.7 and mean years of education for controls = 15.1
± 2.5). In addition, CRP levels in RA patients (mean = 3.3 ±
3.9) did not differ significantly from CRP levels in controls
(mean = 2.5 ± 3.5). Finally, resting systolic blood pressures
(SBPs) in the controls (mean = 122.8 ± 9.6 mmHg) did not
differ from SBPs in the RA patients (mean = 122.1 ± 18.8
mmHg). Similarly, diastolic blood pressures in the controls
(mean = 70.1 ± 6.0 mmHg) and RA patients (mean = 64.4 ±
10.7 mmHg) were similar (P > 0.10).Arthritis Research & Therapy    Vol 11 No 3    Edwards et al.
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All RA patients were receiving treatment for their disease,
though with significant variability in the treatment regimens.
The following is a summary of the disease-modifying antirheu-
matic drugs (DMARDs) taken by the 19 RA patients in this
study: methotrexate (MTX) monotherapy (n = 8), hydroxychlo-
rochloroquine monotherapy (n = 2), TNF antagonist mono-
therapy (n = 3), MTX + other non-biologic DMARD (n = 4),
and MTX + TNF antagonist (n = 2).
Questionnaires
In terms of questionnaire responses, RA patients did report
higher levels of current and recent pain and lower scores on
indices of health and physical functioning relative to the con-
trols (Table 1). Interestingly, patients and controls did not differ
on self-report of current stress levels or the SF-36 indices of
mental/emotional health. RA patients did endorse higher
scores on the BDI, although mean levels of depressive symp-
toms were low and within the normal range (that is, BDI scores
of less than 10 are generally considered subclinical) for both
groups.
Pain responses
Comparisons between RA patients and controls on measures
of psychophysical pain responses yielded statistically signifi-
cant (P ≤ 0.05) or near-significant differences on a number of
measures. RA patients had lower HPThs, lower mechanical
pain thresholds on the thumb, higher pain intensity ratings of
51°C heat stimuli and heat after-sensations, lower cold pain
tolerance, and higher cold pain ratings during the CPT tests.
Tendencies that did not reach the level of frank statistical sig-
nificance were noted for PPTh on the trapezius and heat pain
Table 1
Comparison of rheumatoid arthritis patients and controls on pain and questionnaire responses
RA patients
(n = 19)
Controls
(n = 21)
P value
Responses to noxious stimuli
HPTh, °C 41.4 ± 5.1 44.4 ± 4.5 0.05
PPTh on leg, kPa 665.5 ± 287.7 811.3 ± 400.1 0.19
PPTh on thumb, kPa 295.7 ± 141.6 395.7 ± 150.7 0.03
PPTh on trapezius, kPa 404.5 ± 160.7 536.2 ± 276.9 0.08
Cold pain rating (0 to 100) at midpoint 82.3 ± 12.6 65.4 ± 25.6 0.01
Cold pain rating (0 to 100) at conclusion 83.0 ± 12.4 67.7 ± 24.8 0.02
Cold pain tolerance, seconds 61.8 ± 54.1 111.8 ± 63.8 0.01
Heat pain rating at 49°C 74.4 ± 25.1 57.7 ± 34.7 0.09
Heat pain rating at 51°C 86.8 ± 16.2 68.2 ± 32.4 0.03
Painful heat after-sensations 16.8 ± 23.2 5.7 ± 9.4 0.05
Questionnaire data
Current pain (0 to 10) 3.2 ± 2.3 0.4 ± 0.3 < 0.001
Current stress (0 to 10) 2.2 ± 2.4 1.2 ± 1.9 0.17
Beck Depression Inventory score 7.0 ± 6.3 2.5 ± 3.0 0.01
SF-36, subscale score
General health 52.9 ± 20.3 84.0 ± 19.4 < 0.001
Physical functioning 42.1 ± 24.2 69.1 ± 26.7 0.002
Physical role 28.9 ± 31.5 86.9 ± 28.1 < 0.001
Bodily pain 44.2 ± 21.3 85.7 ± 23.7 < 0.001
Energy/fatigue 53.4 ± 18.4 67.6 ± 18.1 0.02
Mental health 80.7 ± 13.7 81.0 ± 14.5 0.95
Emotional role 84.2 ± 34.0 93.7 ± 22.7 0.30
Social functioning 70.4 ± 27.7 94.6 ± 7.5 0.001
Data are presented as mean ± standard deviation. HPTh, heat pain threshold; PPTh, pressure pain threshold; RA, rheumatoid arthritis; SF-36, 
Short Form Health Survey-36.Available online http://arthritis-research.com/content/11/3/R61
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ratings in response to the 49°C stimuli. These data are pre-
sented in Table 1.
Physiological responses
Repeated measures ANOVAs were used to evaluate
between-group differences in levels of cortisol, IL-6, and TNF-
α over the course of the session. As the demographics of the
groups were similar, we did not control for age, gender, race,
or education, but SF-36 general health subscale scores were
entered as a covariate in order to statistically control for clear
group differences in perceived health. For measures of serum
cortisol, there was a strong main effect of time [F(4,34) = 8.3,
P < 0.01], but no significant main effect of group or group ×
time interaction (P > 0.1). For IL-6, there was also a main effect
of time [F(4,34) = 4.0, P < 0.01] as well as a trend for a main
effect of group [(F(1,37) = 3.2, P = 0.07]. On average, the RA
patients had serum IL-6 levels that tended to be higher than
those of the controls at every time point. The IL-6 data showed
no interaction between group × time. Finally, for the TNF-α
data, the main effects of time and group were qualified by a
significant interaction [F(4,34) = 3.3, P = 0.02]. Among the
RA patients, serum TNF-α increased significantly from base-
line following the pain testing (P < 0.05), whereas no signifi-
cant changes in TNF-α were observed in the controls.
Cortisol, IL-6, and TNF-α data are depicted in Figure 1.
Although our sample of 19 RA patients is too small to permit
extensive investigation of the relationships between cytokine
responses to pain and clinical variables, we assessed correla-
tions of TNF-α and IL-6 responses with the SF-36 subscales
of bodily pain, energy/fatigue, and physical functioning. Within
the RA group, TNF-α levels were unrelated to bodily pain or
physical functioning but showed a tendency to relate to lower
levels of energy (or higher levels of fatigue): r = -0.43, P =
0.07. IL-6 levels were similarly associated with bodily pain (r =
-0.41, P = 0.08), energy/fatigue (r = -0.45, P = 0.06), and
physical functioning (r = -0.42, P = 0.08).
Discussion
The present findings are consistent with previous research
suggesting that RA patients exhibit reduced quality of life rela-
tive to controls [39-41]. Interestingly, though, these effects are
relatively specific in the present study to measures of pain and
physical functioning (that is, the RA and control groups did not
differ on the SF-36 subscales that evaluate mental health and
emotional functioning). Moreover, our findings complement
previous work indicating that individuals with RA are more sen-
sitive to a variety of modalities of noxious stimulation relative to
a healthy comparison group [19-26]. These data suggest that
RA patients display hyperalgesia to mechanical and thermal
stimuli at both disease-affected sites (that is, PPTh on the
thumb was lower in RA patients relative to controls) and many
non-joint sites (that is, on the skin of the forearm, HPThs were
lower and heat pain ratings were higher in RA patients). The
generalized nature of the enhanced sensitivity to pain
observed in these patients suggests alterations in pain
processing at the level of the central nervous system, as we
[42] and others [43,44] have hypothesized.
To our knowledge, this is the first investigation to report differ-
ences between RA patients and controls in physiological
responses to acute, standardized, non-tissue-damaging, nox-
ious stimulation. Although prior work had indicated that stress
is likely to play a significant role in the maladaptive functioning
of neuroendocrine and inflammatory processes in patients
with RA [1-3], the physiological perturbations associated with
pain perception had not previously been evaluated. The
present findings reveal that, in treated RA patients compared
with controls, acute pain induction is associated with eleva-
tions in serum TNF-α levels that last for at least 1 hour. These
data are consistent with the notion that the experience of pain
is associated with enhanced release of pro-inflammatory
cytokines, which in turn sensitize the nervous system, promot-
ing a further amplification of pain transmission [11-14]. While
several other human studies had documented the presence of
cytokine reactivity to the application of calibrated noxious stim-
uli [15,16,18], these results indicate that such reactivity (at
least for TNF-α) may be magnified in the context of RA. Stres-
sors such as pain activate a cascade of neurohumoral events,
many of which may be dysregulated in RA patients, who show
a maladaptively pro-inflammatory response to various types of
stress [4,5]. Moreover, a relative hypo-responsiveness of the
autonomic nervous system and HPA system have been
observed in RA patients [1,3,45,46], although we did not find
group differences in this study in the response of cortisol to
acute pain. The acute increase in cortisol following painful
stimulation is consistent with prior studies [47], but it is impor-
tant to note that stress responses in RA patients are complex
and vary as a function of the stimulus. For example, in contrast
to pain as a stressor, exercise stress does not induce cortisol
increases in either RA patients or controls [48]. However, an
insulin tolerance stress test resulted in a finding of hypocorti-
solemia among the RA patients relative to controls [49], and
similar results were obtained using a combined stressor of
exercise, cold pain, and mental stress [50]. Thus, rather than a
global generalized hypo-responsiveness of the HPA axis to
stress in RA, there appears to be a significant stimulus specif-
icity to stress response profiles.
The greater reactivity of TNF-α and the potentially chronic ele-
vations in IL-6 levels in RA patients are likely to have deleteri-
ous long-term consequences. TNF-α upregulates a number of
inflammatory processes, and the resulting inflammatory cas-
cade leads directly to joint-damaging events such as cartilage
breakdown and resorption of bone. In addition, IL-6 induces
muscle and joint hyperalgesia [51,52] and mediates the devel-
opment of injury-induced hyperalgesia [53]. Following surgery,
IL-6 levels are associated with postoperative pain [54-56] and
reduced functioning [57]. Even in this small sample of RA
patients, we find suggestive correlations of TNF-α and IL-6 lev-Arthritis Research & Therapy    Vol 11 No 3    Edwards et al.
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els with indices of fatigue, pain, and physical function. In the
future, longitudinal studies will likely be helpful in evaluating
potential causal links between cytokine reactivity to acute pain
and outcomes such as physical disability and joint damage. In
addition, larger-sample studies that can group RA patients as
a function of treatment (for example, using TNF antagonists
versus not) will be important in evaluating the role of differing
pharmacologic regimens in shaping these associations. It is
especially interesting that the present findings were observed
in a sample of treated RA patients with, on average, low to
moderate levels of disease activity and CRP levels that were
not different from the controls.
Some important limitations of this study will need to be
addressed in later research. We did not include a pain-free
control session and hence we cannot exclude the possibility
Figure 1
Changes in serum levels of (a) cortisol, (b) interleukin-6 (IL-6), and (c) tumor necrosis factor-alpha (TNF-α) over the course of the session Changes in serum levels of (a) cortisol, (b) interleukin-6 (IL-6), and (c) tumor necrosis factor-alpha (TNF-α) over the course of the session. Data are 
presented as mean ± 95% confidence interval. RA, rheumatoid arthritis.Available online http://arthritis-research.com/content/11/3/R61
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that the elevated TNF-α reactivity in the RA patients was due
to factors other than pain. In addition, our measure of TNF-α
reactivity showed no sign of decline at our final assessment
point, 1 hour after the end of painful stimulation. Thus, we are
not able to determine the full time course of this reactivity to
pain and it is possible that the increases in TNF-α in the RA
patients continued over longer durations. It would also have
been desirable to obtain measurements, at the same time
points, on other factors that have been linked to pain
responses such as anti-inflammatory cytokines [58], catecho-
lamines [59], growth hormone [60], and blood pressure reac-
tivity (a useful index of sympathetic nervous system activation
in the context of pain responses [61,62]). Also lacking in this
study were any data on prior food consumption during the day
of testing. Although we standardized the time of day, the tim-
ing and content of a meal can influence basal cytokine levels
[63,64]. Future studies in this area may wish to more strin-
gently control for such factors. Finally, this cross-sectional
study does not have the capacity to determine the causal links
between RA disease processes and cytokine reactivity to pain.
It is possible, for example, that pre-existing individual differ-
ences in pro-inflammatory cytokine responses to acute stress,
perhaps conferred by genotype or early environmental experi-
ence, represent a risk factor for the development of RA or
other systemic inflammatory diseases. Alternatively, dysregula-
tion of stress responses may be solely a function of the dis-
ease itself. Additional longitudinal research methodologies will
be necessary to illuminate such questions.
In spite of these limitations, this study highlights the impor-
tance of pain and stress in patients with RA. It is important to
note that a handful of studies have suggested that, under non-
stress conditions, basal TNF-α levels may be comparable
between RA patients and controls [65,66]. In the present
investigation, we find that, at baseline, serum TNF-α does not
differ significantly between groups; it is only following the
stressor of acute pain that differences between RA patients
and controls emerge. Future studies of the pathophysiology of
RA would likely benefit from the consideration of such acute
stress and pain levels. Moreover, future clinical trials of analge-
sics in RA may provide opportunities to examine the effects of
pain-relieving treatment on inflammatory activity. Finally, in
future studies, the isolation of specific cell populations in
cytokine assays or the use of stimulation techniques that per-
mit quantification of cytokine production on a 'per-cell' basis
[5] would potentially provide valuable information about the
molecular and cellular processes that underpin these
observed findings.
Conclusions
Compared with controls, RA patients show elevations in pain
sensitivity in response to multiple stimulus modalities across
several body sites. In addition, RA patients display higher lev-
els of serum IL-6 and enhanced pain-reactivity of serum levels
of TNF-α. Abnormal pro-inflammatory responses to painful
stimulation may play a deleterious role in shaping the long-term
symptomatology of RA.
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